![](https://news.europawire.eu/wp-content/uploads/2014/08/Boehringer-Ingelheim.gif)
For Non-US/Non-UK/Non-Canadian Media New analyses highlight undertreatment of high-risk AF patients1,2 First Phase II data demonstrating anticoagulant prescribing patterns in North America now available from GLORIA™-AF Registry Program Results presented at American College of Cardiology 64th Annual Scientific Session & … Read the full press release